

# LURIE CANCER CENTER ONCOSET SYMPOSIUM

## The Promise (and Pitfalls) of Liquid Biopsy

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Chair:

**David VanderWeele, MD, PhD**

Date:

**April 28 , 2023**



**IN PERSON EVENT** 8:30 A.M. - 4:05 P.M. | NORTHWESTERN MEMORIAL HOSPITAL - FEINBERG PAVILION

8:30 a.m. **Registration, Breakfast, and Exhibits**

9:30 a.m. **Welcome**

**David VanderWeele, MD, PhD**

*Lurie Cancer Center*

## SESSION 1: Liquid Biopsy: Understanding the Assays

---

9:35 a.m. **Technical Aspects and Utility of Liquid Biopsy**

**Colin Pritchard, MD, PhD**

*University of Washington Brotman Baty Institute for Precision Medicine*

10:05 a.m. **Pitfalls of Liquid Biopsy Assays**

**Pedram Razavi, MD, PhD**

*Memorial Sloan Kettering Cancer Center*

10:35 a.m. **Break and Exhibits**

## KEYNOTE ADDRESS

---

10:45 a.m. **Molecular/Minimal Residual Disease and Cancer Interception in Solid Tumors -  
A New Paradigm?**

**Lillian L. Siu, MD, FRCPC**

*Princess Margaret Cancer Centre*

11:30 a.m. **Lunch and Exhibits**

## SESSION 2: Disease-Specific Implementation

---

12:30 p.m. **Implementation of Liquid Biopsy for HPV-related Cancers**

**Jochen Lorch, MD**

*Lurie Cancer Center*

1:00 p.m. **Implementation of Liquid Biopsy for Thoracic Oncology**

**Jyoti Patel, MD**

*Lurie Cancer Center*

1:30 p.m. **Break and Exhibits**

1:45 p.m. **Implementation of Liquid Biopsy for Breast Cancer**  
**Dean Tsarwhas, MD**  
*Lurie Cancer Center*

2:15 p.m. **Implementation of Liquid Biopsy for GU Cancers**  
**Christopher George, MD**  
*Lurie Cancer Center*

2:45 p.m. **Break and Exhibits**

### SESSION 3: Future Directions

---

3:00 p.m. **Future Directions of Minimal Residual Disease and Other Liquid Biopsy Assays**  
**Amir Goldkorn, MD**  
*Keck School of Medicine at USC*

3:30 p.m. **Multicancer Early Detection Assays: Excitement and Caution**  
**Erica Vormittag-Nocito, MD**  
*Lurie Cancer Center*

### CONCLUSION

---

4:00 p.m. **Closing Remarks**  
**David VanderWeele, MD, PhD**  
*Lurie Cancer Center*

4:05 p.m. **Adjourn**



**TARGET AUDIENCE:** This activity is intended for healthcare professionals involved in the treatment and care of patients with advanced or refractory cancers for whom precision medicine can help guide treatment choices. This includes medical, surgical, and radiation oncologists, pathologists, radiologists, other translational-oriented laboratory scientists, nurses, pharmacists, and physician assistants.

**LEARNING OBJECTIVES:** (1) Review and compare technical aspects of various cell free DNA assays for the evaluation of solid tumors. (2) Discuss the emerging role of minimal residual disease assays and their implementation in the clinic. (3) Discuss potential limitations of cell free DNA and Minimal Residual Disease assays.

**ACCREDITATION STATEMENT:** The Northwestern University Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**CREDIT DESIGNATION STATEMENT:** The Northwestern University Feinberg School of Medicine designates this live activity for a maximum of 4.75 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**OTHER CREDITS:** The American Academy of Nurse Practitioners and the American Nurses Credentialing Center accept *AMA PRA Category 1 Credits(s)*<sup>™</sup> from organizations accredited by the ACCME.

